Bioinformatic profiling identifies an immune-related risk signature for glioblastoma

Neurology

Volumn 86, Issue 24, 2016, Pages 2226-2234

  Cheng, Wen ^a   Ren, Xiufang ^a   Zhang, Chuanbao ^b   Cai, Jinquan ^c   Liu, Yang ^a   Han, Sheng ^a   Wu, Anhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AIMP1 PROTEIN; CCL18 CHEMOKINE; FCGR2B PROTEIN; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ZBTB16 PROTEIN; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; GENETIC DATABASE; GLIOBLASTOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOPHENOTYPING; LOW RISK PATIENT; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; VALIDATION PROCESS; ADOLESCENT; ADULT; AGED; BIOLOGY; CENTRAL NERVOUS SYSTEM TUMOR; CHINA; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHINA; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RISK; YOUNG ADULT;

EID: 84974731294     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002770     Document Type: Article

References (35)

1. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1-14
2. Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD. The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol 2015; 18: 153-159
3. Finocchiaro G, Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena Curr Opinion Neurol 2011; 24: 641-647
4. Han S, Zhang C, Li Q, et al. Tumour-infiltrating CD4(1) and CD8(1) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 2014; 110: 2560-2568
5. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-Treatment neutrophil-To-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 2015; 15: 617
6. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109
7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280
8. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550
9. Cheng W, Li M, Cai J, et al. HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. J Neuro Oncol 2015; 122: 303-312
10. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837
11. ChengW, Ren X, Cai J, et al. A five-miRNA signature with prognostic and predictive value for MGMT promotermethylated glioblastoma patients. Oncotarget 2015; 6: 29285-29295
12. Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol 2015; 5: 153
13. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12: 1113-1125
14. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012; 14: 584-595
15. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2011; 59: 1169-1180
16. Ridley A, Cavanagh JB. Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 1971; 94: 117-124
17. Farmer JP, Antel JP, Freedman M, Cashman NR, Rode H, Villemure JG. Characterization of lymphoid cells isolated from human gliomas. J Neurosurg 1989; 71: 528-533
18. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2012; 60: 502-514
19. Mock A, Warta R, Geisenberger C, et al. Printed peptide arrays identify prognostic TNC serum antibodies in glioblastoma patients. Oncotarget 2015; 6: 13579-13590
20. Fine HA. New strategies in glioblastoma: exploiting the new biology. Clin Cancer Res 2015; 21: 1984-1988
21. Han S, Huang Y, Wang Z, Li Z, Qin X, Wu A. Increased rate of positive penicillin skin tests among patients with glioma: insights into the association between allergies and glioma risk. J Neurosurg 2014; 121: 1176-1184
22. Kim YH, Jung TY, Jung S, et al. Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 2012; 26: 21-27
23. Bohman LE, Gallardo J, Hankinson TC, et al. The survival impact of postoperative infection in patients with glioblastoma multiforme. Neurosurgery 2009; 64: 828-834; discussion 834-835
24. Samaras V, Piperi C, Korkolopoulou P, et al. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem 2007; 304: 343-351
25. Tchirkov A, Khalil T, Chautard E, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 2007; 96: 474-476
26. Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 2005; 12: 930-933
27. Wagner S, Czub S, Greif M, et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 1999; 82: 12-16
28. Cai J, Zhang W, Yang P, et al. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS One 2015; 10: e0126022
29. Campbell IL, Erta M, Lim SL, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 2014; 34: 2503-2513
30. Jin X, Kim SH, Jeon HM, et al. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain 2012; 135: 1055-1069
31. Liu Q, Li G, Li R, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neuro Oncol 2010; 100: 165-176
32. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17: 1603-1615
33. Wild AT, Ye X, Ellsworth SG, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2015; 38: 259-265
34. Campian JL, Ye X, Brock M, Grossman SA. Treatmentrelated lymphopenia in patients with stage III non-smallcell lung cancer. Cancer Invest 2013; 31: 183-188
35. Hayes J, Thygesen H, Tumilson C, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol 2015; 9: 704-714